In preclinical studies, pelabresib treatment results in downregulation of NF-κB signaling activity, accompanied by loss of viability in ABC- diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) cell lines. Here, NFKB1 is linked to diffuse large B-cell lymphoma.